Altimmune Commences Underwritten Public Offering of Stock and Warrants
ALT is trading near its 52-week low of $2.87 (1.7% above the low).
Summary
Altimmune announced the commencement of an underwritten public offering of common stock and accompanying common stock warrants. This financing move follows the recent shareholder approval on April 16 to increase the company's authorized common stock, which paved the way for such a capital raise. While the proceeds are intended to fund the critical Phase 3 trial for its lead drug pemvidutide and for general corporate purposes, the offering of new shares and warrants is typically dilutive for existing shareholders. This event is likely to exert downward pressure on the stock, especially given that it is currently trading near its 52-week low. Investors will now watch for the final terms and pricing of the offering to assess the full dilutive impact.
At the time of this announcement, ALT was trading at $2.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $451.3M. The 52-week trading range was $2.87 to $7.73. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.